Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

TSX:RVX - Post Discussion

Resverlogix Corp > Pfizer's COVID-19 pill could have real impact....
View:
Post by narmac on Jan 21, 2022 7:54am

Pfizer's COVID-19 pill could have real impact....

...in Canada — if we can roll it out fast enough!!!!,,,,,,News headline!!!!


https://www.cbc.ca/news/health/pfizer-pill-paxlovid-canada-covid-19-rollout-hospitalization-1.6318097

After Canada approved a new treatment for COVID-19, Pfizer's highly effective oral therapeutic Paxlovid, experts are  hopeful the highly sought after pill can help control a devastating Omicron-driven surge — if it's rolled out fast enough.

"I think it will be an effective tool in high-risk individuals if they can get tested quick enough to be able to be in the window for therapeutic benefit," said Dr. Amesh Adalja, an infectious diseases physician and senior scholar at the Johns Hopkins Center for Health Security in Baltimore. 

 

"If you can get it to people fast enough to keep them from needing hospitalizations, then that basically solves the major problem that we're facing."

But questions remain as to whether the provinces and territories will be able to get the drug out to sick, vulnerable Canadians within the recommended five-day window, helping to ease the pressure on hospitals until current COVID-19 levels subside.

"Obviously this is a very promising development, but there's still some work that lies ahead," Dr. Isaac Bogoch, an infectious diseases physician and member of Ontario's COVID-19 vaccine task force, told CBC News Network on Monday.

"That's fantastic we've crossed that first step. We also now, of course, need to distribute it to the provinces and to have the provinces work out how it's actually going to be administered."

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities